GEP identified common changes in OPM2 cells treated either with lenalidomide or with CRBN shRNA. GEP analysis was performed on OPM2 cells either treated with lenalidomide for 48 and 72 hours or transduced with CRBN shRNA (for 48 and 72 hours). (A) The numbers of genes that have expression changed at least 2-fold in both treatments (lenalidomide vs vehicle and CRBN shRNA vs NT shRNA) are summarized at the top. Overall, 123 gene changes were shared between lenalidomide treatment and CRBN knockdown. Those 123 genes were uploaded as the input list for generation of biologic networks using MetaCore pathway analysis. (B) Illustration of one of the top scored networks from active experiments. Green lines indicate activation; red lines, inhibition; and gray lines, unspecified. Red circles represent up-regulated genes; and blue circles, down-regulated genes. (C) Western blot analysis was performed to detect IRF4 expression in HMCLs treated either with lenalidomide or transfected with CRBN shRNA.